Atara biotherapeutics announces early-stage data from multiple sclerosis treatment

Atara biotherapeutics announces all progressive multiple sclerosis patients with sustained disability improvement at six months confirmed improvement at 12 months in the phase 1a study of ata188.atara biotherapeutics inc - patients who achieved sdi at any timepoint maintained it at all future timepoints.atara biotherapeutics inc - higher proportion of patients showing sdi with increasing dose.atara biotherapeutics inc - patients achieving sdi also demonstrated trend toward improvement in fatigue and physical function at 12 months.atara biotherapeutics inc - first available data from open label expansion show patients with sdi at 12 months, maintained sdi at later time points.
ATRA Ratings Summary
ATRA Quant Ranking